A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose-sparing strategies. Here, we evaluate the SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a populat...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gils, Marit J., van Willigen, Hugo D.G., Wynberg, Elke, Han, Alvin X., van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Oomen, Melissa, Tejjani, Khadija, Bouhuijs, Joey H., Verveen, Anouk, Lebbink, Romy, Dijkstra, Maartje, Appelman, Brent, Lavell, A.H. Ayesha, Caniels, Tom G., Bontjer, Ilja, van Vught, Lonneke A., Vlaar, Alexander P.J., Sikkens, Jonne J., Bomers, Marije K., Russell, Colin A., Kootstra, Neeltje A., Sanders, Rogier W., Prins, Maria, de Bree, Godelieve J., de Jong, Menno D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668345/
https://www.ncbi.nlm.nih.gov/pubmed/35103254
http://dx.doi.org/10.1016/j.xcrm.2021.100486
Descripción
Sumario:The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose-sparing strategies. Here, we evaluate the SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a population-based cohort. One week after first vaccine dose, spike protein antibody levels are 27-fold higher and neutralizing antibody titers 12-fold higher, exceeding titers of fully vaccinated SARS-CoV-2-naive controls, with minimal additional boosting after the second dose. Neutralizing antibody titers against four variants of concern increase after vaccination; however, overall neutralization breadth does not improve. Pre-vaccination neutralizing antibody titers and time since infection have the largest positive effect on titers following vaccination. COVID-19 severity and the presence of comorbidities have no discernible impact on vaccine response. In conclusion, a single dose of BNT162b2 vaccine up to 15 months after SARS-CoV-2 infection offers higher neutralizing antibody titers than 2 vaccine doses in SARS-CoV-2-naive individuals.

Ejemplares similares